Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)–2 h infusion for 5 days–as first-line treatment for advanced low grade non-Hodgkin“s lymphoma.

Fridrik, MA; Jäger, G; Kienzer, HR; Hausmaninger, H; Oppitz, P; Krieger, O; Zabernigg, A; Lang, A; Neubauer, M; Weidinger, G; Schiller, L; Seewann, HL; Chott, A; Linkesch, W; Eur J Cancer. 1998; 34(10): 1560-1564.

Leg ulcers associated with long-term hydroxyurea therapy.

Weinlich, G; Schuler, G; Greil, R; Kofler, H; Fritsch, P; J Am Acad Dermatol. 1998; 39(2 Pt 2): 372-374.

Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults.

Topar, G; Staudacher, C; Geisen, F; Gabl, C; Fend, F; Herold, M; Greil, R; Fritsch, P; Sepp, N; Am J Clin Pathol. 1998; 109(3):279-285

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R; Blood. 1998; 91(11): 4273-4281.

Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.

Villunger, A; Egle, A; Kos, M; Egle, D; Tinhofer, I; Henn, T; Uberall, F; Maly, K; Greil, R; Br J Haematol. 1998; 102(4): 1069-1080.

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil, R; Egle, A; Villunger, A; Leuk Lymphoma. 1998; 31(5-6): 477-490.

Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) versus cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, VP-16, methotrexate, dexamethasone (CEOP/IMVP-Dexa) for aggressive non-Hodgkinxxxs lymphoma. A multicenter randomized trial of the Austrian working party medical oncology.

Fridrik, MA; Hausmaninger, H; Greil, R; Lang, A; Drach, J; Fortelny, A; Krieger, O; Lin, W BLOOD. 1999; 94(10): 261B-261B.

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H; Eur J Cancer. 1999; 35(3): 380-385.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz, R; Hausmaninger, H; Haider, K; Kubista, E; Samonigg, H; Gnant, M; Manfreda, D; Tschurtschenthaler, G; Kolb, R; Stierer, M; Fridrik, M; Mlineritsch, B; Steindorfer, P; Mittlböck, M; Steger, G; J Clin Oncol. 1999; 17(6): 1701-1709.

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin“s disease from 1969 to 1994.

Greil, R; Holzner, B; Kemmler, G; Kopp, M; Buchowski, A; Oberaigner, W; Fritsch, E; Dirnhofer, S; Rueffer, U; Diehl, V; Sperner-Unterweger, B; Eur J Cancer. 1999; 35(5): 698-706.